Innoviva Inc (INVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.35B
Last updated: Nov 17, 2026 at 11:06 AM ET
Innoviva Inc (INVA) Competitors
The companies most similar to Innoviva are Inhibrx Biosciences (INBX), Nurix Therapeutics (NRIX) and Vir Biotechnology (VIR). By market cap, Innoviva ranks 9th of the 13 companies on this page; Vera Therapeutics (VERA) is the largest at $2.03B.
Peer Comparison
INVA's ROIC of 10.8% is above the peer median of -66.3%, and its revenue growth of -1.6% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Innoviva (INVA) | $1.35B | 5.3x | 3.0x | 44.1% | 10.8% | -1.6% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Novavax Inc (NVAX) | $1.41B | N/A | 3.2x | -18.6% | -66.6% | -3.0% | 0.00% |
| Inventiva Sa (IVA) | $879.90M | N/A | 133.4x | 0.0% | -327.7% | -76.7% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Trevi Therapeutics Inc (TRVI) | $1.95B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $1.41B | 50.8x | 8.4x | 0.0% | -66.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Innoviva, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Novavax Inc (NVAX) | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases... | NVAX competitors |
| Inventiva Sa (IVA) | Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic... | |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Trevi Therapeutics Inc (TRVI) | Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious... | TRVI competitors |
Frequently Asked Questions About INVA
Who are Innoviva's main competitors?
The companies most similar to Innoviva include Inhibrx Biosciences (INBX), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Novavax (NVAX) and Inventiva Sa (IVA), listed from the closest match.
Who is Innoviva's biggest competitor?
Vera Therapeutics (VERA) is the largest of the similar companies at $2.03B; Inhibrx Biosciences (INBX) is the closest match by business profile, size, sector and industry.
How does INVA stock compare with its competitors?
INVA's P/E is 5.3x against a peer median of 50.8x; its P/S is 3.0x against a peer median of 8.4x; its net margin is 44.1% against a peer median of 0.0%.
Which of Innoviva's competitors pays a higher dividend?
Innoviva pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Innoviva bigger than its competitors?
No. Innoviva is 9th by market cap among the 13 companies on this page; the largest is Vera Therapeutics (VERA) at $2.03B.
INVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors